drugset / Trial / NCT07032272
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.
Timeline
- Start
- 2025-07-23
- Primary completion
- 2025-10-12
- Completion
- 2025-10-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remibrutinib | Small molecule | — | Oral |